Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gennao Bio Inc. is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This single action is assigned to 1 distinct examiner, BRISTOL, LYNN ANNE. The prosecution of this portfolio is currently focused on a single front, which requires a precise response to the issues raised by the examiner.
The data indicates that 1 distinct art unit is responsible for the examination of the company's pending matter. BRISTOL, LYNN ANNE is designated as the busiest examiner, holding 1 busiest examiner pending action. This concentration of the workload under 1 distinct examiner within 1 distinct art unit suggests that the prosecution strategy does not need to account for conflicting examiner styles.
For a practitioner, the presence of 1 pending office action means that resources can be dedicated to resolving this specific case. Because there is only 1 distinct art unit involved, the legal team can focus on the specific precedents and examination trends common to that group. The fact that the busiest examiner pending count is 1 confirms that there are no other pending actions requiring attention across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18177571 | HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF | BRISTOL, LYNN ANNE | 47d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18177571 | HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 47d | Pending | Mar 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial